Published in Ophthalmol Ther on September 17, 2013
Dose uniformity of loteprednol etabonate ophthalmic gel (0.5%) compared with branded and generic prednisolone acetate ophthalmic suspension (1%). Clin Ophthalmol (2013) 0.78
Impact of the Topical Ophthalmic Corticosteroid Loteprednol Etabonate on Intraocular Pressure. Adv Ther (2016) 0.78
Topical delivery of aqueous micellar resolvin E1 analog (RX-10045). Int J Pharm (2015) 0.77
A retrospective analysis of the postoperative use of loteprednol etabonate gel 0.5% following laser-assisted in situ keratomileusis or photorefractive keratectomy surgery. Clin Ophthalmol (2015) 0.76
Intraocular Implants for the Treatment of Autoimmune Uveitis. J Funct Biomater (2015) 0.76
Effects of topical corticosteroid administration on intraocular pressure in normal and glaucomatous cats. Vet Ophthalmol (2016) 0.75
Comparison of Loteprednol with Fluorometholone after Myopic Photorefractive Keratectomy. J Ophthalmic Vis Res (2017) 0.75
Comparison of the Safety and Efficacy of Loteprednol Etabonate 0.5%/Tobramycin 0.3% with Dexamethasone 0.1%/Tobramycin 0.3% Following Strabismus Surgery. Eurasian J Med (2016) 0.75
Therapeutic potential of AAV-mediated MMP-3 secretion from corneal endothelium in treating glaucoma. Hum Mol Genet (2017) 0.75
Small-molecule inhibition of Wnt signaling abrogates dexamethasone-induced phenotype of primary human trabecular meshwork cells. Exp Cell Res (2017) 0.75
Antiinflammatory action of glucocorticoids--new mechanisms for old drugs. N Engl J Med (2005) 8.65
TOPICAL CORTICOSTEROIDS AND HEREDITY IN PRIMARY OPEN-ANGLE GLAUCOMA. Am J Ophthalmol (1964) 2.58
INTRAOCULAR PRESSURE RESPONSE TO TOPICAL CORTICOSTEROIDS. Invest Ophthalmol (1965) 2.39
Gene structure and properties of TIGR, an olfactomedin-related glycoprotein cloned from glucocorticoid-induced trabecular meshwork cells. J Biol Chem (1998) 2.13
Loteprednol etabonate 0.5% versus prednisolone acetate 1.0% for the treatment of inflammation after cataract surgery. J Cataract Refract Surg (2012) 2.08
Corticosteroid-induced ocular hypertension and glaucoma: a brief review and update of the literature. Curr Opin Ophthalmol (2006) 2.06
Cellular pharmacology and molecular biology of the trabecular meshwork inducible glucocorticoid response gene product. Ophthalmologica (1997) 1.98
Corticosteroid-induced glaucoma: a review of the literature. Eye (Lond) (2006) 1.88
Intraocular pressure-raising potential of 1.0% rimexolone in patients responding to corticosteroids. Arch Ophthalmol (1996) 1.81
Controlled evaluation of loteprednol etabonate and prednisolone acetate in the treatment of acute anterior uveitis. Loteprednol Etabonate US Uveitis Study Group. Am J Ophthalmol (1999) 1.73
The role of steroids in outflow resistance. Exp Eye Res (2008) 1.71
Locally administered ocular corticosteroids: benefits and risks. Drug Saf (2002) 1.50
Soft drug design: general principles and recent applications. Med Res Rev (2000) 1.46
A randomized, double-masked, placebo-controlled, multicenter comparison of loteprednol etabonate ophthalmic suspension, 0.5%, and placebo for treatment of keratoconjunctivitis sicca in patients with delayed tear clearance. Am J Ophthalmol (2004) 1.39
Dexamethasone-induced ocular hypertension in perfusion-cultured human eyes. Invest Ophthalmol Vis Sci (1995) 1.25
Difluprednate ophthalmic emulsion 0.05% for postoperative inflammation and pain. J Cataract Refract Surg (2009) 1.23
Intraocular pressure response to loteprednol etabonate in known steroid responders. J Ocul Pharmacol (1993) 1.18
The effect of early steroid treatment after PRK on clinical and refractive outcomes. Acta Ophthalmol Scand (2001) 1.14
Corticosteroids and glaucoma risk. Drugs Aging (1999) 1.13
Effects of loteprednol/tobramycin versus dexamethasone/tobramycin on intraocular pressure in healthy volunteers. Cornea (2008) 1.08
Identification of high intraocular pressure responders to topical ophthalmic corticosteroids. J Ocul Pharmacol (1993) 1.08
Control of intraocular inflammation associated with cataract surgery. Curr Opin Ophthalmol (2000) 1.06
Control of intra-ocular inflammation associated with cataract surgery. Curr Opin Ophthalmol (2001) 1.05
Gene expression profiles of human trabecular meshwork cells induced by triamcinolone and dexamethasone. Invest Ophthalmol Vis Sci (2008) 1.04
Double-masked, placebo-controlled evaluation of loteprednol etabonate 0.5% for postoperative inflammation. Loteprednol Etabonate Post-operative Inflammation Study Group 1. J Cataract Refract Surg (1998) 1.03
Long-term safety of loteprednol etabonate 0.2% in the treatment of seasonal and perennial allergic conjunctivitis. Eye Contact Lens (2004) 1.02
Advances in corticosteroid therapy for ocular inflammation: loteprednol etabonate. Int J Inflam (2012) 1.02
Ophthalmic drug design based on the metabolic activity of the eye: soft drugs and chemical delivery systems. AAPS J (2005) 1.01
Comparison of in vitro potency of corticosteroids with ability to raise intraocular pressure. Am J Ophthalmol (1975) 0.99
Change in intraocular pressure during long-term use of loteprednol etabonate. J Glaucoma (1998) 0.99
A double-masked, placebo-controlled evaluation of 0.5% loteprednol etabonate in the treatment of postoperative inflammation. The Loteprednol Etabonate Postoperative Inflammation Study Group 2. Ophthalmology (1998) 0.98
Basic sciences in clinical glaucoma: steroids, ocular hypertension, and glaucoma. J Glaucoma (1995) 0.98
Comparison of the safety and efficacy of loteprednol 0.5%/tobramycin 0.3% with dexamethasone 0.1%/tobramycin 0.3% in the treatment of blepharokeratoconjunctivitis. Curr Med Res Opin (2008) 0.95
Visual loss caused by corticosteroid-induced glaucoma: how to avoid it. Retina (2009) 0.95
Treatment of ocular inflammatory conditions with loteprednol etabonate. Br J Ophthalmol (2008) 0.95
A controlled evaluation of the efficacy and safety of loteprednol etabonate in the prophylactic treatment of seasonal allergic conjunctivitis. Loteprednol Allergic Conjunctivitis Study Group. Am J Ophthalmol (1997) 0.94
Effects of dexamethasone, diclofenac, or placebo on the inflammatory response after cataract surgery. Br J Ophthalmol (2002) 0.94
Efficacy and safety of rimexolone 1% versus prednisolone acetate 1% in the control of postoperative inflammation following phacoemulsification cataract surgery. Int Ophthalmol (2004) 0.94
A double-masked, placebo-controlled evaluation of the efficacy and safety of loteprednol etabonate in the treatment of giant papillary conjunctivitis. The Loteprednol Etabonate Giant Papillary Conjunctivitis Study Group I. Am J Ophthalmol (1997) 0.93
Loteprednol etabonate: clinical potential in the management of ocular inflammation. BioDrugs (1998) 0.93
Attenuation of ocular hypertension with the use of topical loteprednol etabonate 0.5% in steroid responders after corneal transplantation. Cornea (2009) 0.92
A randomized, double-masked, placebo-controlled parallel study of 0.2% loteprednol etabonate in patients with seasonal allergic conjunctivitis. J Allergy Clin Immunol (1998) 0.91
A randomized, double-masked, placebo-controlled parallel study of loteprednol etabonate 0.2% in patients with seasonal allergic conjunctivitis. Ophthalmology (1999) 0.91
Difluprednate ophthalmic emulsion 0.05% (Durezol) administered two times daily for managing ocular inflammation and pain following cataract surgery. Clin Ophthalmol (2010) 0.90
Loteprednol etabonate gel 0.5% for postoperative pain and inflammation after cataract surgery: results of a multicenter trial. Clin Ophthalmol (2012) 0.89
Efficacy and safety of rimexolone 1% ophthalmic suspension vs 1% prednisolone acetate in the treatment of uveitis. Am J Ophthalmol (1996) 0.89
Rimexolone 1% versus prednisolone acetate in preventing early postoperative inflammation after cataract surgery. Int Ophthalmol (2007) 0.89
A multicenter, randomized, parallel-group, clinical trial comparing the safety and efficacy of loteprednol etabonate 0.5%/tobramycin 0.3% with dexamethasone 0.1%/tobramycin 0.3% in the treatment of Chinese patients with blepharokeratoconjunctivitis. Curr Med Res Opin (2012) 0.88
Efficacy and safety of loteprednol etabonate 0.5% gel in the treatment of ocular inflammation and pain after cataract surgery. J Cataract Refract Surg (2012) 0.88
The effects of Rimexolone 1% in postoperative inflammation after cataract extraction. A double-masked placebo-controlled study. Eur J Ophthalmol (1998) 0.87
Comparative study of the intraocular pressure effects of fluorometholone 0.1% versus dexamethasone 0.1%. Br J Ophthalmol (1983) 0.87
A double-masked, placebo-controlled evaluation of the efficacy and safety of loteprednol etabonate in the treatment of giant papillary conjunctivitis. CLAO J (1997) 0.87
Effects of anti-inflammatory drugs following cataract extraction. Curr Opin Ophthalmol (2001) 0.84
Inflammatory response after phacoemulsification treated with 0.5% prednisolone acetate or vehicle. Graefes Arch Clin Exp Ophthalmol (2008) 0.83
Control of ocular inflammation after cataract extraction with rimexolone 1% ophthalmic suspension. J Cataract Refract Surg (1997) 0.83
Risk factors for steroid response among cataract patients. J Cataract Refract Surg (2011) 0.82
Ocular allergy treatment. Immunol Allergy Clin North Am (2008) 0.82
Efficacy and tolerability of a fixed-dose moxifloxacin - dexamethasone formulation for topical prophylaxis in LASIK: a comparative, double-masked clinical trial. Clin Ophthalmol (2008) 0.81
The genetic problem of chronic simple glaucoma. Ann Ophthalmol (1971) 0.81
Loteprednol and tobramycin in combination: a review of their impact on current treatment regimens. Expert Opin Pharmacother (2010) 0.81
Treatment of seasonal allergic conjunctivitis with ophthalmic corticosteroids: in search of the perfect ocular corticosteroids in the treatment of allergic conjunctivitis. Curr Opin Allergy Clin Immunol (2010) 0.81
Comparison of topical prednisolone acetate, ketorolac tromethamine and fluorometholone acetate in reducing inflammation after phacoemulsification. J Med Assoc Thai (2003) 0.81
Genetic factors related to glaucoma. Ann N Y Acad Sci (1968) 0.81
A randomized, comparative study of fluorometholone 0.2% and fluorometholone 0.1% acetate after photorefractive keratectomy. Eur J Ophthalmol (2000) 0.80
Developments in ocular allergy. Curr Opin Allergy Clin Immunol (2004) 0.80
Comparison of topical 0.7% dexamethasone-cyclodextrin with 0.1% dexamethasone sodium phosphate for postcataract inflammation. Graefes Arch Clin Exp Ophthalmol (2005) 0.80
Use of surodex in phacotrabeculectomy surgery. Am J Ophthalmol (2005) 0.79
Ultrastructural and morphometric study of corticosteroid glaucoma in rabbits. Ophthalmic Res (1984) 0.79
Double-blind controlled trial to compare anti-inflammatory effects of tolmetin 2%, prednisolone 0.5%, and placebo in post-cataract extraction eyes. Br J Ophthalmol (1986) 0.77
The biological properties of Org 6216, a new type of steroid with a selective local anti-inflammatory action. Arzneimittelforschung (1980) 0.76
Ocular pressure response to fluorometholone acetate and dexamethasone sodium phosphate. Curr Eye Res (1984) 0.76
Impending corneal perforation after collagen cross-linking for herpetic keratitis. J Cataract Refract Surg (2013) 2.13
Assessment of corneal biomechanical properties and their variation with age. Curr Eye Res (2007) 1.61
Automated keratometry in routine cataract surgery: comparison of Scheimpflug and conventional values. J Cataract Refract Surg (2011) 1.39
Adult human Müller glia cells are a highly efficient source of rod photoreceptors. Stem Cells (2011) 1.20
Analysis of limbal stem cell deficiency by corneal impression cytology. Cornea (2003) 1.14
Assessment of the epithelium's contribution to corneal biomechanics. Exp Eye Res (2007) 1.14
Biomechanical properties of human and porcine corneas. Exp Eye Res (2008) 1.12
Regional variation in the biomechanical properties of the human sclera. Exp Eye Res (2010) 1.10
"Salt and pepper" corneal endothelium. Ophthalmology (2013) 1.07
Safety and efficacy of topical infliximab in a mouse model of ocular surface scarring. Invest Ophthalmol Vis Sci (2013) 1.05
Concise review: hurdles in a successful example of limbal stem cell-based regenerative medicine. Stem Cells (2014) 1.04
Experimental assessment of corneal anisotropy. J Refract Surg (2008) 1.04
Characterization of age-related variation in corneal biomechanical properties. J R Soc Interface (2010) 1.02
Biological parameters determining the clinical outcome of autologous cultures of limbal stem cells. Regen Med (2013) 1.00
Molecular basis for keratoconus: lack of TrkA expression and its transcriptional repression by Sp3. Proc Natl Acad Sci U S A (2005) 0.92
Age-related variations in the biomechanical properties of human sclera. J Mech Behav Biomed Mater (2012) 0.90
Isolation and genotyping of Acanthamoeba strains from corneal infections in Italy. J Med Microbiol (2010) 0.89
Intraocular production and release of nerve growth factor after iridectomy. Invest Ophthalmol Vis Sci (2002) 0.88
The CORTES study: corneal transplant indications and graft survival in an Italian cohort of patients. Cornea (2006) 0.87
In vitro evidence of nerve growth factor effects on human conjunctival epithelial cell differentiation and mucin gene expression. Invest Ophthalmol Vis Sci (2009) 0.87
Anterior uveitis complicating zoledronic acid infusion. Ocul Immunol Inflamm (2009) 0.87
Cogan syndrome in children: early diagnosis and treatment is critical to prognosis. Am J Ophthalmol (2004) 0.84
Efficacy of valacyclovir vs acyclovir for the prevention of recurrent herpes simplex virus eye disease: a pilot study. Am J Ophthalmol (2007) 0.84
Experimental assessment of human corneal hysteresis. Curr Eye Res (2008) 0.84
Visual outcome in ocular sarcoidosis: retrospective evaluation of risk factors. Eur J Ophthalmol (2011) 0.82
Trigeminal stereotactic electrolysis induces dry eye in mice. Acta Ophthalmol (2012) 0.81
Atypical toxoplasmosis masquerading late occurrence of typical findings. Eur J Ophthalmol (2009) 0.81
Numerical study of the effect of corneal layered structure on ocular biomechanics. Curr Eye Res (2009) 0.81
Nerve growth factor (NGF): an important molecule for trophism and healing of the ocular surface. Adv Exp Med Biol (2002) 0.81
Rapid molecular identification of fungal pathogens in corneal samples from suspected keratomycosis cases. J Med Microbiol (2006) 0.81
Telomerase activity is sufficient to bypass replicative senescence in human limbal and conjunctival but not corneal keratinocytes. Eur J Cell Biol (2004) 0.80
Topical treatment with nerve growth factor in an animal model of herpetic keratitis. Graefes Arch Clin Exp Ophthalmol (2007) 0.80
Double-biguanide therapy for resistant acanthamoeba keratitis. Case Rep Ophthalmol (2011) 0.80
Scheimpflug keratometry versus conventional automated keratometry in routine cataract surgery. J Cataract Refract Surg (2010) 0.79
Severe keratitis following corneal cross-linking for keratoconus. Acta Ophthalmol (2010) 0.79
Central Corneal Thickness Reproducibility among Ten Different Instruments. Optom Vis Sci (2016) 0.78
Tumor necrosis factor-α inhibitors as a treatment of corneal hemangiogenesis and lymphangiogenesis. Eye Contact Lens (2015) 0.77
Direct sequencing of Scedosporium apiospermum DNA in the diagnosis of a case of keratitis. J Med Microbiol (2005) 0.77
Reply: Corneal collagen crosslinking and herpetic keratitis. J Cataract Refract Surg (2013) 0.75
In vivo confocal microscopy in goldenhar syndrome: a case report. BMC Ophthalmol (2013) 0.75
Substance P and its Inhibition in Ocular Inflammation. Curr Drug Targets (2016) 0.75
VesselJ: A New Tool for Semiautomatic Measurement of Corneal Neovascularization. Invest Ophthalmol Vis Sci (2015) 0.75